BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling

Blood

Volumn 112, Issue 8, 2008, Pages 3154-3163

  Jeanpierre, Sandrine ^a,e   Nicolini, Franck Emmanuel ^f   Kaniewski, Bastien ^a,d   Dumontet, Charles ^a,b,e   Rimokh, Ruth ^a,c,e   Puisieux, Alain ^a,e   Maguer Satta, Véronique ^a,c,d,e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

^d CENTRE LÉON BÉRARD   (France)

^e EA 1892   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENIC PROTEIN RECEPTOR; CARRIER PROTEIN; FOLLISTATIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; STAT PROTEIN; THROMBOPOIETIN; UNCLASSIFIED DRUG; ACTIVIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CD34 ANTIGEN; JANUS KINASE 1; PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD34 SELECTION; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; BIOLOGICAL MODEL; BIOSYNTHESIS; BONE MARROW CELL; CYTOLOGY; METABOLISM; THROMBOCYTE COUNT;

ACTIVINS; ANTIGENS, CD34; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; HUMANS; JANUS KINASE 1; MEGAKARYOCYTES; MODELS, BIOLOGICAL; PLATELET COUNT; PROTEIN KINASES; SIGNAL TRANSDUCTION; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 54049103653     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-145326     Document Type: Article

References (47)

1. Chan JY, Watt SM. Adhesion receptors on haematopoietic progenitor cells. Br J Haematol. 2001;112:541-557.
2. Pang L, Weiss MJ, Poncz M. Megakaryocyte biology and related disorders. J Clin Invest. 2005; 115:3332-3338.
3. Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res. 2003;282:110-120.
4. Kim SJ. Letterio J. Transforming growth factorbeta signaling in normal and malignant hematopoiesis. Leukemia. 2003;17:1731-1737.
5. Shav-Tal Y, Zipori D. The role of activin a in regulation of hemopoiesis. Stem Cells. 2002;20:493-500.
6. Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006;116:1195-1201.
7. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836-841.
8. Jay KE, Gallacher L, Bhatia M. Emergence of muscle and neural hematopoiesis in humans. Blood. 2002;100:3193-3202.
9. Maguer-Satta V, Rimokh R. FLRG, member of the follistatin family, a new player in hematopoiesis. Mol Cell Endocrinol. 2004;225:109-118.
10. Maguer-Satta V, Forissier S, Bartholin L. et al. A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin. Exp Cell Res. 2006;312: 434-442.
11. Maeno M, Mead PE, Kelley C, et al. The role of BMP-4 and GATA-2 in the induction and differentiation of hematopoietic mesoderm in Xenopus laevis. Blood. 1996;88:1965-1972.
12. Bhatia M, Bonnet D. Wu D, et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med. 1999;189:1139-1148.
13. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood. 2007;109:2679-2687.
14. Zon Ll. Self-renewal vs differentiation, a job for the mighty morphogens. Nat Immunol. 2001;2: 142-143.
15. Sadlon TJ, Lewis ID, D'Andrea RJ. BMP4: its role in development of the hematopoietic system and potential as a hematopoietic growth factor. Stem Cells. 2004;22:457-474.
16. Huber TL, Zhou Y, Mead PE, Zon Ll. Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm. Blood. 1998;92: 4128-4137.
17. Hutton JF, Rozenkov V, Khor FS, D'Andrea RJ, Lewis ID. Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stromanon contact co-culture system. Stem Cells Dev. 2006;15:805-813.
18. Rajan P, Panchision DM, Newell LF, McKay RD. BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol. 2003;161:911-921.
19. Wagner TU. Bone morphogenetic protein signaling in stem cells: one signal, many consequences. FEBS J. 2007;274:2968-2976.
20. Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995;9:2105-2116.
21. Johansson BM, Wiles MV. Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. Mol Cell Biol. 1995;15:141-151.
22. Li F, Lu S, Vida L, Thomson JA, Honig GR. Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro. Blood. 2001;98:335-342.
23. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 2007;3:30-38.
24. Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells. 2001;19:397-407.
25. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115: 3339-3347.
26. Guerriero R, Parolini I, Testa U, et al. Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci. 2006;119:744-752.
27. Blair A, Baker CL, Pamphilon DH, Judson PA. Ex vivo expansion of megakaryocyte progenitor cells from normal bone marrow and peripheral blood and from patients with haematological malignancies. Br J Haematol. 2002;116:912-919.
28. Raslova H, Baccini V, Loussaief L, et al. Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood. 2006:107:2303-2310.
29. Martinovic S, Mazic S, Kisic V, et al. Expression of bone morphogenetic proteins in stromal cells from human bone marrow long-term culture. J Histochem Cytochem. 2004;52:1159-1167.
30. Fox NE, Kaushansky K. Engagement of integrin alpha4beta1 enhances thrombopoietin-induced megakaryopoiesis. Exp Hematol. 2005;33:94-99.
31. Ungerer M, Peluso M, Gillitzer A, et al. Generation of functional culture-derived platelets from CD34+ progenitor cells to study transgenes in the platelet environment. Circ Res. 2004;95:36-44.
32. Mattia G, Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood. 2002;99:888-897.
33. Kalina U, Koschmieder S, Hofmann WK, et al. Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells. Exp Hematol. 2001;29:602-608.
34. Perry JM, Harandi OF, Paulson RF. BMP4, SCF, and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors. Blood. 2007;109:4494-4502.
35. Pick M, Azzola L, Mossman A, Stanley EG, Elefanty AG. Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis. Stem Cells. 2007;25:2206-2214.
36. Deconinck AE, Mead PE, Tevosian SG, et al. FOG acts as a repressor of red blood cell development in Xenopus. Development. 2000;127: 2031-2040.
37. Fossett N, Tevosian SG, Gajewski K, et al. The Friend of GATA proteins U-shaped, FOG-1, and FOG-2 function as negative regulators of blood, heart, and eye development in Drosophila. Proc Natl Acad Sci U S A. 2001;98:7342-7347.
38. Murone M, Carpenter DA, de Sauvage FJ. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells. 1998;16:1-6.
39. Bunting S, Widmer R, Lipari T, et al. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood. 1997;90: 3423-3429.
40. Levin J, Cocault L, Demerens C, et al. Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response. Blood. 2001;98:1019-1027.
41. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10: 64-71.
42. Gainsford T, Nandurkar H, Metcalf D, et al. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood. 2000;95:528-534.
43. Sipe JB, Zhang J, Waits C, et al. Localization of bone morphogenetic proteins (BMPs)-2,-4, and -6 within megakaryocytes and platelets. Bone. 2004;35:1316-1322.
44. Ciurea SO, Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol. 2007;44:166-182.
45. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. Aust N Z J Surg. 2007;77:626-631.
46. Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007;109:3024-3030.
47. Kaban K, Kantarjian H, Talpaz M, et al. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000;88:570-576.